CapsoVision: third-quarter revenue up 1% as AI Highlights goes on sale
CapsoVision reported third-quarter revenue up 1%, while gross margin slipped to 49%. The company targets an FDA submission for CapsoCam Colon before year-end 2026.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, CapsoVision's third-quarter revenue rose 1% year on year, but gross margin fell to 49%. The company linked the decline to higher costs and a one-time charge.
The FDA-cleared AI Highlights product has launched in the United States. The submission for the CapsoCam Colon capsule colonoscopy system is targeted before the end of 2026.
why it matters
This is a niche medical device company, so the story is unlikely to move broader markets. Investors in medtech shares will watch margin trends and the timing of regulatory approvals for new products.
tags
instruments
sources
- CV: AI Highlights launched as CapsoCam Colon neared its planned year-end FDA submission — TradingView, 12 November 2026 at 22:36 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗